Accession Number : ADP008819
Title : Clinical Study of a New Therapy for Nerve Agent Poisoning: Ascending Dose Tolerance Study of HI-6 + Atropine.
Corporate Author : DEFENCE RESEARCH ESTABLISHMENT SUFFIELD RALSTON (ALBERTA)
Personal Author(s) : Clement, J. G. ; Bailey, D. G. ; Madill, H. D. ; Spence, J. D.
Report Date : 13 MAY 1993
Pagination or Media Count : 10
Abstract : HI-6 was rapidly absorbed from an IM injection site. Maximum HI-6 plasma concentrations of 1.88, 4.96, 8.31 & 15.0 ug/ml were found 28-36 min after administration and maintained above 4 ug/ml concentration for 0, 39, 112 & 172.5 min following administration of 62.5, 125, 250 or 500 mg HI-6 + atropine (2 mg), respectively. The calculated half life of HI-6 was 78.2 min following 62.5 mg HI-6 + atropine dose and approximately 64-67 min following 125-500 mg HI-6 + atropine doses. Approximately 50 % of the total dose of HI-6 was eliminated unchanged in the urine. There were significant changes (p < 0.05) in AST, CPK, creatinine and gamma GT following the 500 mg HI-6 + atropine dose but they were not considered to be clinically significant. Urinalysis, hematology and semen analysis over the 24 hr observation period was uneventful. There were no clinically significant changes in heart rate or ECG trace, respiration or blood pressure, visual and mental acuity following HI-6 + atropine.
Descriptors : *ATROPINE, *PHARMACOKINETICS, ACUITY, BLOOD PRESSURE, CREATININE, CANADA, INTRAMUSCULAR INJECTIONS, HALF LIFE, HEART RATE, HEMATOLOGY, OBSERVATION, RESPIRATION, URINALYSIS.
Subject Categories : Pharmacology
Distribution Statement : APPROVED FOR PUBLIC RELEASE